Abstract
Dry mouth is a common side effect of psychotropic drugs, and it decreases treatment compliance and the quality of life (QOL) of patients. Several studies have revealed that the histamine (H2)-receptor blocker nizatidine promotes salivation through its anticholinesterase activity. The aim of this study was to evaluate the effect of nizatidine on salivation in patients who were on psychotropic treatment and complained of dry mouth. The study population comprised 22 such patients (16 women and 6 men; average age, 53.1 years [standard deviation, 14.8 years]). These patients were administered nizatidine (Acinon) for 8 weeks, and the subjective symptoms of dry mouth were observed at 0, 4, and 8 weeks. An improvement was noted in the subjective symptoms at 4 and 8 weeks. Therefore, it appears that nizatidine is effective in alleviating dry mouth in patients receiving psychotropic drugs.
